TECH is off the screens on one check: a base has formed.
✕A base has formedNo pause of 3 weeks or more inside the last 24 weeks.
–Long enough to countNeeds a base first.
–Shallow enoughNeeds a base first.
–Close to its pivotNeeds a base first.
✓Relative strengthRS 83 against 70 needed.
Measured against the base-and-breakout thresholds. The other screens use their own numbers, so a name can miss here and still be a fair-looking chart.
Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year
Support and resistance
Support below
None within the last 120 sessions
Resistance above
None within the last 120 sessions
Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.
The read
Bio-Techne Corp. is not on any of the screens right now. Its relative strength rating is 83, and it sits in Biotechnology.
Against its industry
UnconfirmedNone of the patterns above holds.
One month against its industry
-2.5%
Three months against its industry
+7.5%
Six months against its industry
+33.4%
Read against an equal-weighted index of Biotechnology, which is +22.6% against the S&P 500 over six months Partly aligned.
Nothing dated in the next three months that we can ingest automatically.
How it moves on earnings
On average 4.1% either way across its last 8 reports.
Checking your subscription…
Close before the report day to close after it, so it holds whether the company reported before the open or after the close.
The business
Revenue
$1.2B
+4.6% year on year
Operating margin
19.6%
gross 65.8%
Net margin
—
Free cash flow
$308.2M
2.7% of market cap
Price to sales
9.31×
Price to earnings
—
not meaningful on a loss
Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.
The latest quarter, read by fixed rules · reported Nov 6
Key takeaway
Profitable and cash generating; the question is growth.
Revenue
$299.7M
-6.7% QoQ · +4.6% YoY
Gross margin
65.6%
-0.2 pts QoQ
Net income
$28.3M
Positive
Free cash flow
$67.2M
Cash generating
What the numbers say
·Revenue +4.6% year over year, -6.7% on the quarter
·Gross margin 65.6%, -0.2 points on the quarter
▲Good: Profitable: net income $28M, operating margin 12.2%
Key question: Can the cash generation hold as growth slows?
The next test is whether the quarter repeats.
From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.
Tracked funds
Held by 6 of 46 tracked funds at the end of Q3 2026.
Last quarter: 1 bought new, 1 added, 4 trimmed, 1 sold out.
Checking your subscription…
From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.
Flagged by the market sweep
Closed above its 20- and 50-day on heavy volumeTape · 2026-11-06
above 20d & 50d on 1.6x volume at 72.66
Mixed: stocks have outrun random stocks by 0.2% over three sessions, not consistently enough to call (1,668 cases over 60 nights). Against their own sector they have lagged by 0.7%.
From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.
Headlines link to the publisher. We do not host, summarise or rank them, and a headline appearing here is not a view about the company.
Insiders
Nobody bought or sold on the open market in the last 6 months. There were 35 filings for awards, option exercises or shares withheld to pay tax — those happen on a vesting schedule, so they are not a decision to buy or sell.
Most recent filings
2026-11-01Kelderman Kim· Chief Executive Officer, Directorwithheld for tax2,385$173,294
2026-11-01Hippel James· CFOoption exercise11,545
2026-11-01Hippel James· CFOwithheld for tax5,096$370,275
2026-10-29Vessey Rupert· Directoraward2,750
2026-10-29Seth Alpna· Directoraward2,750
2026-10-29Klimovsky Judith V.· Directoraward2,750
2026-10-29Herr Amy E.· Directoraward2,750
2026-10-29KEEGAN JOSEPH D· Directoraward2,750
From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.
What analysts expect
Strong buy0
Buy0
Hold12
Sell1
Strong sell0
These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.
Checking your subscription…
Gamma concentration
No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.